Kyverna Therapeutics (NASDAQ:KYTX) Posts Earnings Results, Beats Expectations By $0.09 EPS

Kyverna Therapeutics (NASDAQ:KYTX) released its earnings results on Tuesday. The company reported ($0.66) EPS for the quarter, beating the consensus estimate of ($0.75) by $0.09, FiscalAI reports.

Kyverna Therapeutics Trading Up 2.5%

NASDAQ:KYTX traded up $0.26 during midday trading on Wednesday, reaching $10.49. 745,924 shares of the stock traded hands, compared to its average volume of 859,373. The company has a fifty day moving average of $8.93 and a 200 day moving average of $8.32. Kyverna Therapeutics has a 12 month low of $2.06 and a 12 month high of $13.67. The company has a debt-to-equity ratio of 0.11, a quick ratio of 7.75 and a current ratio of 7.75. The stock has a market capitalization of $634.90 million, a P/E ratio of -2.86 and a beta of 2.05.

Analyst Upgrades and Downgrades

KYTX has been the subject of several analyst reports. Weiss Ratings restated a “sell (d-)” rating on shares of Kyverna Therapeutics in a research report on Friday, March 27th. Wall Street Zen downgraded Kyverna Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, March 21st. Finally, HC Wainwright reissued a “buy” rating and issued a $20.00 target price on shares of Kyverna Therapeutics in a research note on Thursday, April 23rd. Four equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $28.67.

Institutional Investors Weigh In On Kyverna Therapeutics

Large investors have recently added to or reduced their stakes in the company. Adage Capital Partners GP L.L.C. bought a new position in shares of Kyverna Therapeutics during the fourth quarter valued at about $15,667,000. Balyasny Asset Management L.P. bought a new stake in shares of Kyverna Therapeutics in the fourth quarter worth about $9,220,000. Alyeska Investment Group L.P. purchased a new position in Kyverna Therapeutics during the 4th quarter valued at about $5,640,000. Heights Capital Management Inc. bought a new position in Kyverna Therapeutics during the 4th quarter valued at approximately $2,555,000. Finally, Woodline Partners LP bought a new position in Kyverna Therapeutics during the 3rd quarter valued at approximately $1,513,000. Institutional investors own 18.08% of the company’s stock.

Kyverna Therapeutics Company Profile

Kyverna Therapeutics is a clinical‐stage biotechnology company dedicated to developing engineered regulatory T‐cell (Treg) therapies for the treatment of autoimmune and inflammatory diseases. Leveraging a proprietary platform for the isolation, expansion and modification of Treg cells, the company aims to restore immune homeostasis in patients by delivering antigen‐specific cell therapies that selectively target diseased tissues while minimizing systemic immunosuppression.

The company’s lead programs include an allogeneic Treg candidate in clinical development for ulcerative colitis, with additional preclinical assets focused on rheumatoid arthritis and other chronic inflammatory conditions.